CL2004000303A1 - Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. - Google Patents
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.Info
- Publication number
- CL2004000303A1 CL2004000303A1 CL200400303A CL2004000303A CL2004000303A1 CL 2004000303 A1 CL2004000303 A1 CL 2004000303A1 CL 200400303 A CL200400303 A CL 200400303A CL 2004000303 A CL2004000303 A CL 2004000303A CL 2004000303 A1 CL2004000303 A1 CL 2004000303A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrimidins
- triazines
- pharmaceutical composition
- preparation process
- compounds derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03100411 | 2003-02-20 | ||
US47501203P | 2003-06-02 | 2003-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2004000303A1 true CL2004000303A1 (es) | 2005-04-08 |
Family
ID=32910137
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200400306A CL2004000306A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
CL200400303A CL2004000303A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200400306A CL2004000306A1 (es) | 2003-02-20 | 2004-02-19 | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
Country Status (27)
Country | Link |
---|---|
US (2) | US7442705B2 (es) |
EP (2) | EP1597238B1 (es) |
JP (2) | JP4586013B2 (es) |
KR (2) | KR20050094896A (es) |
CN (2) | CN1751031B (es) |
AP (1) | AP2005003373A0 (es) |
AR (2) | AR044499A1 (es) |
AT (2) | ATE506353T1 (es) |
AU (2) | AU2004213186B2 (es) |
BR (2) | BRPI0407741B8 (es) |
CA (2) | CA2516589C (es) |
CL (2) | CL2004000306A1 (es) |
CY (1) | CY1106788T1 (es) |
DE (2) | DE602004006383T2 (es) |
DK (1) | DK1597238T3 (es) |
EA (2) | EA010423B1 (es) |
ES (1) | ES2287734T3 (es) |
HR (2) | HRP20050821A2 (es) |
IL (2) | IL169596A (es) |
MX (2) | MXPA05008866A (es) |
MY (1) | MY138308A (es) |
NO (2) | NO20054311L (es) |
NZ (2) | NZ541601A (es) |
PL (2) | PL227295B1 (es) |
PT (1) | PT1597238E (es) |
TW (2) | TW200500346A (es) |
WO (2) | WO2004074261A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
WO2005016893A2 (en) | 2003-07-30 | 2005-02-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
RU2416616C2 (ru) | 2005-01-19 | 2011-04-20 | Райджел Фармасьютикалз, Инк. | Пролекарства соединений 2,4-пиримидиндиамина и их применения |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
RU2597364C2 (ru) | 2005-11-01 | 2016-09-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
CA2642229C (en) | 2006-02-24 | 2015-05-12 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
ES2618057T3 (es) * | 2006-12-29 | 2017-06-20 | Janssen Sciences Ireland Uc | Pirimidinas 5,6-sustituidas inhibidoras del VIH |
CN101573343B (zh) * | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
EA029131B1 (ru) | 2008-05-21 | 2018-02-28 | Ариад Фармасьютикалз, Инк. | Фосфорсодержащие производные в качестве ингибиторов киназы |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
TW201008933A (en) * | 2008-08-29 | 2010-03-01 | Hutchison Medipharma Entpr Ltd | Pyrimidine compounds |
GEP20135793B (en) | 2008-09-11 | 2013-03-25 | Pfizer | Heteroaryls amide derivatives and their use as glucokinase activators |
AR074209A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
AU2010222589B2 (en) | 2009-03-11 | 2012-08-16 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US9249124B2 (en) | 2011-03-30 | 2016-02-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase inhibitors and methods of making and using thereof |
WO2012151561A1 (en) | 2011-05-04 | 2012-11-08 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN110818690B (zh) | 2016-07-26 | 2021-08-10 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
AU2020274011B2 (en) | 2019-05-10 | 2024-02-15 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
AU2020297422B2 (en) | 2019-06-17 | 2024-03-21 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US5691364A (en) | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
EP0862463A1 (en) | 1995-11-23 | 1998-09-09 | Janssen Pharmaceutica N.V. | Solid mixtures of cyclodextrins prepared via melt-extrusion |
NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
SK287996B6 (sk) | 1998-03-27 | 2012-09-03 | Janssen Pharmaceutica N. V. | Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound |
EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
AP1683A (en) | 1998-11-10 | 2006-11-29 | Janssen Pharmaceutica Nv | HIV replication inhibiting pyrimidines. |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
BRPI0009721B1 (pt) | 1999-04-15 | 2018-11-21 | Bristol-Myers Squibb Holdings Ireland | inibidores de tirosina quinase de proteína cíclica |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
UA74797C2 (uk) * | 1999-09-24 | 2006-02-15 | Янссен Фармацевтика Н.В. | Антивірусна композиція |
EP1218360B1 (en) * | 1999-10-07 | 2008-05-28 | Amgen Inc., | Triazine kinase inhibitors |
CA2406562C (en) | 2000-05-08 | 2009-09-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
WO2002036578A2 (en) * | 2000-10-31 | 2002-05-10 | Lynn Bonham | Triazine derivatives as lpaat-b inhibitors and uses thereof |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ES2364645T3 (es) * | 2002-02-05 | 2011-09-08 | Astellas Pharma Inc. | Derivado de 2,4,6-triamino-1,3,5-triazina. |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
ATE530530T1 (de) * | 2002-06-28 | 2011-11-15 | Astellas Pharma Inc | Diaminopyrimidincarbonsäureamidderivat |
ATE451104T1 (de) * | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
-
2004
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en active Application Filing
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 EP EP04737252A patent/EP1597238B1/en not_active Expired - Lifetime
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Application Discontinuation
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Application Discontinuation
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 EP EP04737251A patent/EP1603887B1/en not_active Expired - Lifetime
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en active IP Right Grant
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 US US10/545,358 patent/US7442705B2/en active Active
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 US US10/545,719 patent/US7585870B2/en active Active
-
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2005-09-19 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
-
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2004000303A1 (es) | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. | |
CL2004000930A1 (es) | Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos. | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
CL2007003686A1 (es) | Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral. | |
BRPI0716495A2 (pt) | (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos. | |
CL2006001266A1 (es) | Formas solidas cristalinas i, ii, iii, iv y v de tigeciclina; procedimiento de preparacion de las formas cristalinas ii, iv y v; composicion farmaceutica que comprende las formas cristalinas; y su uso para tratar infecciones bacterianas. | |
CL2007002128A1 (es) | Derivados de n'-ciano-n-halogenoalquil-imidamida; procedimiento para la preparacion de dicho compuesto; composiciones farmaceuticas que lo contienen; y uso del compuesto para combatir parasitos animales. | |
CL2007003565A1 (es) | Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih. | |
BRPI0212137A2 (pt) | diidropteridinonas, processos para prepará-las e seu uso como composições farmacêuticas | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
CL2007002649A1 (es) | Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes. | |
BRPI0709266B8 (pt) | 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
BRPI0614205A2 (pt) | composto, composição farmacêutica, e, uso de composto | |
CL2006002831A1 (es) | Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides. | |
CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. | |
BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
CL2008002353A1 (es) | Compuestos derivados de 7h-indolo[2,1-a][2]benzazepina; composicion farmaceutica; y uso en el tratamiento de la hepatitis c. | |
PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
PT103884A (pt) | Composições de libertação prolongada e métodos para a sua preparação | |
CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
EP1845099A4 (en) | ARTIFICIAL DERIVATIVES (QINGHAOSU), SYNTHESIS METHODS AND APPLICATIONS, AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME DERIVATIVES |